The micronutrient application in agriculture takes place through soil application, foliar spraying or added as seed treatments. The latter method, the nutri-priming, is an appealing option due to the easiness in handling it, environment-friendly, cost effectiveness and efficient against multiple environmental stressors. To assess the feasibility of Zn-priming technique on seeds germination, two experiments were conducted and assessed the efficiency on the growth rate, yield and biofortification on the forage maize (Zea mays L.). The first laboratory experiment assessed the effect of Zn-priming for three-time exposures (i.e., 8, 16 and 24 h) on germination parameters. The second experiment was done in a greenhouse, by using the 10 seeds obtained from 24 h priming. Five seed pretreatments were studied (0, 0.1, 0.5, 1 and 11 2 % of zinc sulfate heptahydrate (ZnSO₄·7H₂O)) compared to the recommended dose (5 ppm of Zn at 5–9 leaf stage) provided by soil application. The obtained results revealed that all seed priming, including hydro-priming, improve seed germination performance. Zn-priming increased the grain yield and helped to enrich the seeds in this element, especially seedlings treated with 0.5 % Zn sulphate for 24 h leading to an increase in yield by 47 % and in Zn content by 15 %. The comparison of the results from both techniques showed that Zn-priming could be was very effective than the traditional direct application in soil.

To better understand the potential of drug repurposing in COVID-19, we analyzed control strategies over essential host factors for SARS-CoV-2 infection. We constructed comprehensive directed protein–protein interaction (PPI) networks integrating the top-ranked host factors, the drug target proteins and directed PPI data. We analyzed the networks to identify drug targets and combinations thereof that offer efficient control over the host factors. We validated our findings against clinical studies data and bioinformatics studies. Our method offers a new insight into the molecular details of the disease and into potentially new therapy targets for it. Our approach for drug repurposing is significant beyond COVID-19 and may be applied also to other diseases.